CXCL8 and early-onset autosomal dominant Alzheimer disease: Mamik and Ghorpade believe that targeting CXCL8 and reducing levels of CXCL8 within the brain may reduce immune cell recruitment, and thus prevent certain neuro-inflammatory/degenerative diseases, e.g., Alzheimer’s disease, Parkinson’s disease, HIV-associated neurodegenerative disorder, and possibly depression (151).